Targeting AMPK and the Nrf2/HO-1 axis: a promising therapeutic strategy in acute lung injury Source: Eur Respir J, 58 (6) 2102238; 10.1183/13993003.02238-2021 Year: 2021
A phosphatidylinositol 3-kinase Inhibitor strongly suppressed pulmonary vascular remodeling in a murine model of allergic vasculitis Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015
Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury Source: Eur Respir J 2003; 22: 20-27 Year: 2003
Phosphoinositide 3-kinase ? inhibitor suppresses interleukin-17 expression in a murine asthma model Source: Eur Respir J 2010; 36: 1448-1459 Year: 2010
Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018
Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017
The selective Rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates experimental pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017
Inhibition of phosphatidylinositol 3-kinase and mitogen-activated protein kinase kinase prevents malignant pleural mesothelioma cell growth Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010
Terapeutic potential of different phosphodiesterase inhibitors in a model of acute lung injury Source: Eur Respir J 2004; 24: Suppl. 48, 264s Year: 2004
The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017 Year: 2017
Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery Source: Annual Congress 2013 –Experimental models in critical care Year: 2013
The effect of a novel phosphoinositide 3-kinase Δ inhibitor (PI3KΔ), GSK2269557, on potential biomarkers measured from the lungs of healthy male smokers Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
Effect of PDGF receptor tyrosine kinase inhibitor AG1296 on bleomycin-induced lung fibrosis in mice Source: Annual Congress 2004 - Pulmonary fibrosis - new insights Year: 2004
Differential actions of phosphatidyinositol 3-kinase inhibitors on respiratory burst and leukotriene C4 generation in PAF-stimulated human eosinophils Source: Eur Respir J 2003; 22: Suppl. 45, 547s Year: 2003
Transmission of muscarinic receptor mediated proliferative effects in human lung fibroblasts involves ERK-MAP kinase, but not PI-3 kinase and Rho-kinase pathway Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007
Phosphoinositide 3-kinase δ inhibitor suppresses IL-17 expression in a murine model of asthma Source: Annual Congress 2009 - Animal models of airways inflammation Year: 2009
LATE-BREAKING ABSTRACT: Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009
Inhibition of c-kit tyrosine kinase by sunitinib alleviates airway remodeling in a mouse model of chronic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009